Sibutramine
Instructions for use:
- 1. Pharmacological action
- 2. Analogs
- 3. Indications for use
- 4. Contraindications
- 5. Method of application
- 6. Side effects for weight loss
- 7. Drug interactions
- 8. Storage conditions
Sibutramine is a synthetic medication used in the treatment of alimentary obesity.
pharmachologic effect
Sibutramine with the active ingredient of the same name belongs to drugs that accelerate the onset of satiety. This leads to a decrease in food intake without psychological stress, and, as a result, to weight loss.
Medicines containing sibutramine do not release monoamines and do not belong to MAO inhibitors. Also, the drug has no affinity for adrenergic, serotonergic, muscarinic, dopaminergic, benzodiazepine, histamine and NMDA receptors.
Sibutramine's analogs
Analogs of Sibutramine in terms of the active substance are the drugs Goldline, Meridia, Lindax and Slimia.
If necessary, the doctor can replace the medication with one of the analogs of Sibutramine with a similar therapeutic effect. These include Reduxin, containing sibutramine and microcrystalline cellulose as active components, and Fepranon with the active substance amfepramone.
Indications for the use of Sibutramine
According to the instructions, the drug Sibutramine is prescribed as part of complex maintenance therapy for overweight:
- With alimentary obesity (body mass index - from 30 kg / m2 or more);
- With alimentary obesity (body mass index - from 27 kg / m2 or more), if there are other risk factors associated with overweight, including hyperlipidemia and type 2 diabetes.
Contraindications
It is contraindicated to use Sibutramine for weight loss:
- For severe eating disorders such as bulimia nervosa or anorexia nervosa;
- With an organic cause of obesity;
- Against the background of Tourette's syndrome;
- Against the background of mental illness;
- With occlusive peripheral arterial disease;
- Against the background of ischemic heart disease, congenital heart defects, chronic heart failure in the stage of decompensation;
- With uncontrolled arterial hypertension;
- Against the background of arrhythmias, tachycardia and various disorders of cerebral circulation, including transient;
- Against the background of severe violations of the liver and kidneys;
- With hyperthyroidism;
- Against the background of pheochromocytoma;
- With benign prostatic hyperplasia with the formation of residual urine;
- During pregnancy and lactation;
- With established pharmacological, drug or alcohol dependence;
- Against the background of glaucoma;
- With hypersensitivity to the active substance of the same name or other components that make up the drug.
Sibutramine, according to the instructions, is contraindicated to be used simultaneously with some medicines, namely:
- With MAO inhibitors;
- With antidepressants, neuroleptics, tryptophan, or other drugs that have a depressant effect on the central nervous system;
- With any other medicines, the action of which is aimed at reducing body weight.
The appointment of Sibutramine for weight loss requires special care:
- Against the background of hypokalemia and hypomagnesemia;
- Simultaneously with medications that increase the QT interval;
- Against the background of impaired liver and kidney function, proceeding in mild and moderate severity;
- With epilepsy;
- Concurrently with drugs that can cause high blood pressure and heart rate, including a number of medicines for colds, coughs and allergies.
Due to the lack of necessary research, Sibutramine is not prescribed for instructions to people over 65 years old.
Method of using Sibutramine
Sibutramine is usually prescribed at an initial dose of 10 mg per day. If weight loss occurs too slowly (less than 2 kg per month), in the absence of pronounced side effects associated with taking the medication, the daily dosage is increased to 15 mg. If the rate of weight loss does not increase at the indicated dosage, the use of Sibutramine is canceled.
As a rule, the medicine is used for at least a year. If during the first three months of therapy it is not possible to achieve a sufficient level of weight loss (at least 5% of the initial level), the use of Sibutramine is canceled. Also, the medication is canceled if body weight gain is observed during therapy.
Sibutramine is prescribed only in cases where any other measures taken do not lead to weight loss (less than 5 kg in three months).
Treatment must be comprehensive. This should include changing the diet and increasing physical activity. It is the change in the habitual lifestyle that caused obesity that is a prerequisite for maintaining the achieved weight loss result with the use of Sibutramine.
During therapy, blood pressure and changes in heart rate should be monitored. Also, during the examination, attention should be paid to chest pains, edema, progressive dyspnea.
It is not recommended to drink alcohol while using Sibutramine.
Side effects of Sibutramine for weight loss
Of the disorders of the digestive system, most often when using Sibutramine, according to reviews, there is a loss of appetite, dry mouth, constipation and nausea, a little less often a transient increase in the activity of liver enzymes can develop.
Also, against the background of taking Sibutramine, according to reviews, disorders of other systems may occur, which are expressed as:
- Increased sweating, insomnia, headaches, anxiety, dizziness, paresthesias, seizures and changes in taste (central and peripheral nervous system);
- Purpura Schönlein-Genoch and thrombocytopenia (blood coagulation);
- Feeling of palpitations, tachycardia, a slight increase in blood pressure, redness of the skin with a feeling of warmth, exacerbation of hemorrhoids (cardiovascular system).
In some cases, the use of Sibutramine, according to reviews, can cause acute interstitial nephritis, a more pronounced increase in blood pressure and mesangiocapillary glomerulonephritis.
In most cases, the occurrence of side effects when using Sibutramine for weight loss is observed in the first month of therapy, and their frequency and severity decrease over time.
Drug interactions
During treatment, it should be borne in mind that with the simultaneous use of Sibutramine with ketoconazole, erythromycin, troleandomycin, cyclosporine and other drugs that inhibit the activity of the CYP3A4 isoenzyme, the plasma concentration of Sibutramine metabolites may increase, which contributes to a slight increase in the QT interval.
The risk of developing serotonin syndrome increases with the simultaneous use of Sibutramine with:
- 5-HT1 receptor agonists;
- Selective serotonin reuptake inhibitors such as fluoxetine, citalopram, sertraline and paroxetine;
- Opioid analgesics;
- Ergot alkaloids derivatives;
- Centrally acting antitussive drugs.
Storage conditions
Sibutramine is a prescription drug with standard storage conditions.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
